DexCom Inc Total Liabilities
DexCom Inc total liabilities. Based on the latest financial reports, DexCom Inc (DXCM) has total liabilities worth $3.68 Billion USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check DXCM cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of DexCom Inc (2003–2025)
Total liabilities of DexCom Inc from 2003 to 2025. This chart illustrates how DexCom Inc's total liabilities have evolved over time, based on quarterly financial data. Explore DexCom Inc (DXCM) long-term investment share to see how much of total assets are deployed in long-term investments.
DexCom Inc Competitors by Total Liabilities
The table below lists competitors of DexCom Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Atmos Energy Corporation
NYSE:ATO
|
USA | $4.44 Billion |
|
Mettler-Toledo International Inc
NYSE:MTD
|
USA | $3.66 Billion |
|
Sandoz Group AG
SW:SDZ
|
Switzerland | CHF13.83 Billion |
|
KONE Oyj
HE:KNEBV
|
Finland | €6.23 Billion |
|
Jabil Circuit Inc
NYSE:JBL
|
USA | $22.49 Billion |
|
Heidelberg Materials AG
XETRA:HEI
|
Germany | €16.84 Billion |
|
Banco Bradesco S.A
F:BREC
|
Germany | €2.29 Trillion |
|
TDK Corporation
F:TDKA
|
Germany | €2.03 Trillion |
Liability Composition Analysis (2003–2025)
This chart breaks down DexCom Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see DexCom Inc balance sheet assets.
Liquidity & Leverage Metrics
DexCom Inc Total Liabilities Ratios Explained
DexCom Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.95 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.24 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.55 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how DexCom Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for DexCom Inc (2003–2025)
The table below shows the annual total liabilities of DexCom Inc from 2003 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $3.59 Billion | -17.98% |
| 2024-12-31 | $4.38 Billion | +4.43% |
| 2023-12-31 | $4.20 Billion | +28.71% |
| 2022-12-31 | $3.26 Billion | +12.75% |
| 2021-12-31 | $2.89 Billion | +17.34% |
| 2020-12-31 | $2.46 Billion | +62.92% |
| 2019-12-31 | $1.51 Billion | +20.73% |
| 2018-12-31 | $1.25 Billion | +158.45% |
| 2017-12-31 | $484.70 Million | +307.31% |
| 2016-12-31 | $119.00 Million | +68.08% |
| 2015-12-31 | $70.80 Million | +59.46% |
| 2014-12-31 | $44.40 Million | +15.63% |
| 2013-12-31 | $38.40 Million | +32.41% |
| 2012-12-31 | $29.00 Million | +81.42% |
| 2011-12-31 | $15.98 Million | -1.15% |
| 2010-12-31 | $16.17 Million | -75.27% |
| 2009-12-31 | $65.39 Million | -21.19% |
| 2008-12-31 | $82.98 Million | +18.30% |
| 2007-12-31 | $70.14 Million | +808.09% |
| 2006-12-31 | $7.72 Million | +5.61% |
| 2005-12-31 | $7.31 Million | -90.70% |
| 2004-12-31 | $78.67 Million | +47.41% |
| 2003-12-31 | $53.37 Million | -- |
About DexCom Inc
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick bloo… Read more